TY - JOUR AU - Yusuf, S. AU - Hawken, S. AU - Ôunpuu, S. AU - Dans, T. AU - Avezum, A. AU - Lanas, F. AU - McQueen, M. AU - Budaj, A. AU - Pais, P. AU - Varigos, J. AU - Lisheng, L. PY - 2004 DA - 2004// TI - Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study JO - Lancet VL - 364 UR - https://doi.org/10.1016/S0140-6736(04)17018-9 DO - 10.1016/S0140-6736(04)17018-9 ID - Yusuf2004 ER - TY - JOUR PY - 2009 DA - 2009// TI - Major lipids, apolipoproteins, and risk of vascular disease JO - JAMA VL - 302 UR - https://doi.org/10.1001/jama.2009.1619 DO - 10.1001/jama.2009.1619 ID - ref2 ER - TY - JOUR AU - Wild, S. AU - Roglic, G. AU - Green, A. AU - Sicree, R. AU - King, H. PY - 2004 DA - 2004// TI - Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 JO - Diabetes Care VL - 27 UR - https://doi.org/10.2337/diacare.27.5.1047 DO - 10.2337/diacare.27.5.1047 ID - Wild2004 ER - TY - JOUR AU - Brown, C. D. AU - Higgins, M. AU - Donato, K. A. AU - Rohde, F. C. AU - Garrison, R. AU - Obarzanek, E. AU - Ernst, N. D. AU - Horan, M. PY - 2000 DA - 2000// TI - Body mass index and the prevalence of hypertension and dyslipidemia JO - Obes Res VL - 8 UR - https://doi.org/10.1038/oby.2000.79 DO - 10.1038/oby.2000.79 ID - Brown2000 ER - TY - JOUR AU - Joshi, S. R. AU - Anjana, R. M. AU - Deepa, M. AU - Pradeepa, R. AU - Bhansali, A. AU - Dhandania, V. K. AU - Joshi, P. P. AU - Unnikrishnan, R. AU - Nirmal, E. AU - Subashini, R. AU - Madhu, S. V. PY - 2014 DA - 2014// TI - Prevalence of dyslipidemia in urban and rural India: the ICMR–INDIAB study JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0096808 DO - 10.1371/journal.pone.0096808 ID - Joshi2014 ER - TY - JOUR AU - Mooradian, A. D. PY - 2009 DA - 2009// TI - Dyslipidemia in type 2 diabetes mellitus JO - Nat Rev Endocrinol VL - 5 UR - https://doi.org/10.1038/ncpendmet1066 DO - 10.1038/ncpendmet1066 ID - Mooradian2009 ER - TY - JOUR AU - Reiner, Ž. PY - 2013 DA - 2013// TI - Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update JO - Nutr Metab Cardiovasc Dis VL - 23 UR - https://doi.org/10.1016/j.numecd.2013.05.002 DO - 10.1016/j.numecd.2013.05.002 ID - Reiner2013 ER - TY - JOUR AU - Virani, S. S. PY - 2011 DA - 2011// TI - Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges JO - Texas Heart Inst J VL - 38 ID - Virani2011 ER - TY - JOUR AU - Sosale, A. AU - Saboo, B. AU - Sosale, B. PY - 2015 DA - 2015// TI - Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence JO - Diabetes Metab Syndr Obes VL - 8 UR - https://doi.org/10.2147/DMSO.S49592 DO - 10.2147/DMSO.S49592 ID - Sosale2015 ER - TY - JOUR AU - Balakumar, P. AU - Rose, M. AU - Ganti, S. S. AU - Krishan, P. AU - Singh, M. PY - 2007 DA - 2007// TI - PPAR dual agonists: are they opening Pandora’s Box? JO - Pharmacol Res VL - 56 UR - https://doi.org/10.1016/j.phrs.2007.03.002 DO - 10.1016/j.phrs.2007.03.002 ID - Balakumar2007 ER - TY - JOUR AU - Pai, V. AU - Paneerselvam, A. AU - Mukhopadhyay, S. AU - Bhansali, A. AU - Kamath, D. AU - Shankar, V. AU - Gambhire, D. AU - Jani, R. H. AU - Joshi, S. AU - Patel, P. PY - 2014 DA - 2014// TI - A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V) JO - J Diabetes Sci Technol VL - 8 UR - https://doi.org/10.1177/1932296813518680 DO - 10.1177/1932296813518680 ID - Pai2014 ER - TY - JOUR AU - Jani, R. H. AU - Pai, V. AU - Jha, P. AU - Jariwala, G. AU - Mukhopadhyay, S. AU - Bhansali, A. AU - Joshi, S. PY - 2014 DA - 2014// TI - A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI) JO - Diabetes Technol Ther VL - 16 UR - https://doi.org/10.1089/dia.2013.0253 DO - 10.1089/dia.2013.0253 ID - Jani2014 ER - TY - JOUR AU - Shetty, S. R. AU - Kumar, S. AU - Mathur, R. P. AU - Sharma, K. H. AU - Jaiswal, A. D. PY - 2015 DA - 2015// TI - Observational study to evaluate the safety and efficacy of Saroglitazar in Indian diabetic dyslipidemia patients JO - Indian Heart J VL - 67 UR - https://doi.org/10.1016/j.ihj.2015.02.007 DO - 10.1016/j.ihj.2015.02.007 ID - Shetty2015 ER - TY - STD TI - Thacker H, Shrimanker R, Tulle R. Novel action of Saroglitazar in patients with diabetic dyslipidemia—an observational study. The American Association of Clinical Endocrinologists Annual Meeting Abstracts; 2016, p. 183. https://www.aace.com/files/abstracts-2016.PDF. Accessed 10 May 2019. UR - https://www.aace.com/files/abstracts-2016.PDF ID - ref14 ER - TY - STD TI - Joshi S, Vadgama J, Mody P, Sound R, Jaiswal A. Saroglitazar in the treatment of severe hypertriglyceridemia in patients with type 2 diabetes. The American Association of Clinical Endocrinologists Annual Meeting Abstracts. Late Breaking Abstracts; 2018, p. 304. https://www.aace.com/files/latebreaking_2018.pdf. Accessed 10 May 2019. UR - https://www.aace.com/files/latebreaking_2018.pdf ID - ref15 ER - TY - STD TI - Bhattacharyya S, Bhattacharyya S, Bhattacharyya K. Saroglitazar and its impact on diabetic dyslipidemia: a real life observational study from eastern India. Indian J Basic Appl Med Res. 2018;7(2):298–303. http://ijbamr.com/pdf/March%202018%20298-303%20%20ZZ.pdf. Accessed 10 May 2019. UR - http://ijbamr.com/pdf/March%202018%20298-303%20%20ZZ.pdf ID - ref16 ER - TY - STD TI - Saboo B, Prajapati A, Joshi S, Bhandari S, Shah A, Jaiswal A, Hasnani D. To assess the effect of 4 mg Saroglitazar on patients of diabetes dyslipidemia with nonalcoholic fatty liver disease for 24 weeks at Diabetes Care Centre. The American Diabetes Association 75th Scientific Sessions Abstracts; 2015. https://www.abstractsonline.com/pp8/#!/3699/presentation/9937. Accessed 10 May 2019. UR - https://www.abstractsonline.com/pp8/#!/3699/presentation/9937 ID - ref17 ER - TY - STD TI - Joshi S, Ruby S, Saboo B, Chawla R, Bhandari S. Saroglitazar in non-alcoholic fatty liver disease. The American Association of Clinical Endocrinologists Annual Meeting Abstracts. Late breaking abstracts; 2016, p. 331. https://www.aace.com/files/late-breaking-abstracts-2016.pdf. Accessed 10 May 2019. UR - https://www.aace.com/files/late-breaking-abstracts-2016.pdf ID - ref18 ER - TY - STD TI - Chhaya G, Patel N. Antihyperglycemic action of Saroglitazar in patients with type 2 diabetes mellitus and dyslipidemia. The American Diabetes Association 77th Scientific Sessions Abstracts; 2017. https://www.abstractsonline.com/pp8/#!/4297/presentation/44460. Accessed 10 May 2019. UR - https://www.abstractsonline.com/pp8/#!/4297/presentation/44460 ID - ref19 ER - TY - STD TI - Mohit M, Panda JK, Sharma JK. Observational study to evaluate the safety and efficacy of saroglitazar in diabeticdyslipidemia patients with and without Coronary Artery Disease (CAD). JIMI. 2017;11(6):7–11. http://upchapterapi.com/uploaded/journalPdf/journal_pdf_3_4466.pdf. Accessed 16 May 2019. UR - http://upchapterapi.com/uploaded/journalPdf/journal_pdf_3_4466.pdf ID - ref20 ER - TY - STD TI - Kaul U, Arambam P, Kachru R, Bhatia V, Diana Y, Nungshijungla, Shah M, Parmar K, Jaiswal A, Jain P. A prospective, multicentre, single arm clinical study to evaluate the effect of Saroglitazar on non high-density lipoprotein cholesterol in patients with diabetic dyslipidemia inadequately controlled with diet, exercise, and statin—the GLIDDER Study. J Diabetes Metab. 2019;10:819. https://doi.org/10.4172/2155-6156.1000819. https://www.omicsonline.org/open-access/a-prospective-multicentre-single-arm-clinical-study-to-evaluate-the-effect-of-saroglitazar-on-non-highdensity-lipoprotei.pdf. Accessed 16 May 2019. UR - https://www.omicsonline.org/open-access/a-prospective-multicentre-single-arm-clinical-study-to-evaluate-the-effect-of-saroglitazar-on-non-highdensity-lipoprotei.pdf ID - ref21 ER - TY - STD TI - Goyal O, Goyal P, Chinna RS. Effect of Saroglitazar on non-alcoholic fatty liver disease in patients with diabetic dyslipidemia: a prospective observational study. The 28th Annual Conference of Asian Pacific Association for the Study of the Liver Conference Abstracts. Hepatol Int (2019) 13 (Suppl 1):S1–S266. Abstract#373–S204. https://doi.org/10.1007/s12072-019-09936-5. ID - ref22 ER - TY - STD TI - Chatterjee S, Majumder A, Jaiswal A. Effect of Saroglitazar, a dual PPAR-α/γ agonist, on lipid and glycemic parameters in Indian patients with diabetic dyslipidemia: a 27-week, retrospective analysis. The American Diabetes Association 75th Scientific Sessions Abstracts; 2015. https://www.abstractsonline.com/pp8/#!/3699/presentation/9929. Accessed 10 May 2019. UR - https://www.abstractsonline.com/pp8/#!/3699/presentation/9929 ID - ref23 ER - TY - STD TI - Joshi S, Kesavadev J, Bhandari S, Saboo B, Jaiswal A, Patel P. 9-Month safety and efficacy of saro-glitazar in diabetic dyslipidemia. The American Association of Clinical Endocrinologists Annual Meeting Abstracts. Late breaking abstracts; 2015, p. 291. https://www.aace.com/files/late-breaking-abstracts-2015.pdf. Accessed 10 May 2019. UR - https://www.aace.com/files/late-breaking-abstracts-2015.pdf ID - ref24 ER - TY - STD TI - Chatterjee S, Majumder A, Ray S. Effect of Saroglitazar on metabolic parameters in Indian patients with diabetic dyslipidemia: a 40-week, retrospective analysis. The American Diabetes Association 76th Scientific Sessions Abstracts; 2016. https://www.abstractsonline.com/pp8/#!/4008/presentation/41813. Accessed 10 May 2019. UR - https://www.abstractsonline.com/pp8/#!/4008/presentation/41813 ID - ref25 ER - TY - STD TI - Joshi S, Ghosh S, Shah P, Jaiswal A, Patel P. Saroglitazar in diabetic dyslipidemia: 1-year data. The American Diabetes Association 75th Scientific Sessions Abstracts—Late breaking abstracts; 2015. https://www.abstractsonline.com/pp8/#!/3699/presentation/12818. Accessed 10 May 2019. UR - https://www.abstractsonline.com/pp8/#!/3699/presentation/12818 ID - ref26 ER - TY - STD TI - Aneja P. Effect of Saroglitazar on non-HDL-C in diabetic dyslipidemia. The American Diabetes Association 76th Scientific Sessions Abstracts; 2016. https://www.abstractsonline.com/pp8/#!/4008/presentation/41899. Accessed 10 May 2019. UR - https://www.abstractsonline.com/pp8/#!/4008/presentation/41899 ID - ref27 ER - TY - STD TI - Maheshwari A, Saboo B, Verma N. One-year post-marketing surveillance study of Saroglitazar in patients with diabetic dyslipidemia. The American Diabetes Association 76th Scientific Sessions Abstracts; 2016. https://www.abstractsonline.com/pp8/#!/4008/presentation/44440. Accessed 10 May 2019. UR - https://www.abstractsonline.com/pp8/#!/4008/presentation/44440 ID - ref28 ER - TY - STD TI - Chatterjee A, Mohit M, Jaiswal A. One-year real-time clinical safety and effectiveness of Saroglitazar in patients with diabetic dyslipidemia. The American Diabetes Association 77th Scientific Sessions Abstracts; 2017. https://www.abstractsonline.com/pp8/#!/4297/presentation/43100. Accessed 10 May 2019. UR - https://www.abstractsonline.com/pp8/#!/4297/presentation/43100 ID - ref29 ER - TY - STD TI - Chatterjee S, Majumder A, Ray S, Bhattacharjee K. Observational study of Saroglitazar on metabolic parameters in Indian patients with diabetic dyslipidaemia—a fifty eight weeks of clinical experience. Diabetes Obes Int J 2018;3(2):000180. https://medwinpublishers.com/DOIJ/DOIJ16000180.pdf. Accessed 16 May 2019. UR - https://medwinpublishers.com/DOIJ/DOIJ16000180.pdf ID - ref30 ER - TY - JOUR AU - Staels, B. AU - Fruchart, J. C. PY - 2005 DA - 2005// TI - Therapeutic roles of peroxisome proliferator–activated receptor agonists JO - Diabetes VL - 54 UR - https://doi.org/10.2337/diabetes.54.8.2460 DO - 10.2337/diabetes.54.8.2460 ID - Staels2005 ER - TY - JOUR AU - Tenenbaum, A. AU - Motro, M. AU - Fisman, E. Z. PY - 2005 DA - 2005// TI - Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons JO - Cardiovasc Diabetol VL - 4 UR - https://doi.org/10.1186/1475-2840-4-14 DO - 10.1186/1475-2840-4-14 ID - Tenenbaum2005 ER - TY - JOUR AU - Joshi, S. R. PY - 2015 DA - 2015// TI - Saroglitazar for the treatment of dyslipidemia in diabetic patients JO - Expert Opin Pharmacother VL - 16 UR - https://doi.org/10.1517/14656566.2015.1009894 DO - 10.1517/14656566.2015.1009894 ID - Joshi2015 ER - TY - JOUR AU - Fruchart, J. C. PY - 2017 DA - 2017// TI - Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia JO - Cardiovasc Diabetol VL - 16 UR - https://doi.org/10.1186/s12933-017-0602-y DO - 10.1186/s12933-017-0602-y ID - Fruchart2017 ER - TY - JOUR AU - Jong, M. AU - Worp, H. B. AU - Graaf, Y. AU - Visseren, F. L. AU - Westerink, J. PY - 2017 DA - 2017// TI - Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials JO - Cardiovasc Diabetol VL - 16 UR - https://doi.org/10.1186/s12933-017-0617-4 DO - 10.1186/s12933-017-0617-4 ID - Jong2017 ER - TY - JOUR AU - Balakumar, P. AU - Mahadevan, N. AU - Sambathkumar, R. PY - 2019 DA - 2019// TI - A contemporary overview of PPARα/γ dual agonists for the management of diabetic dyslipidemia JO - Curr Mol Pharmacol UR - https://doi.org/10.2174/1874467212666190111165015 DO - 10.2174/1874467212666190111165015 ID - Balakumar2019 ER - TY - JOUR AU - Stirban, A. O. AU - Andjelkovic, M. AU - Heise, T. AU - Nosek, L. AU - Fischer, A. AU - Gastaldelli, A. AU - Herz, M. PY - 2016 DA - 2016// TI - Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial JO - Diabetes Obes Metab VL - 18 UR - https://doi.org/10.1111/dom.12620 DO - 10.1111/dom.12620 ID - Stirban2016 ER - TY - JOUR AU - Lincoff, A. M. AU - Tardif, J. C. AU - Schwartz, G. G. AU - Nicholls, S. J. AU - Rydén, L. AU - Neal, B. AU - Malmberg, K. AU - Wedel, H. AU - Buse, J. B. AU - Henry, R. R. AU - Weichert, A. PY - 2014 DA - 2014// TI - Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial JO - JAMA VL - 311 UR - https://doi.org/10.1001/jama.2014.3321 DO - 10.1001/jama.2014.3321 ID - Lincoff2014 ER - TY - JOUR AU - Bhosle, D. AU - Bhosle, V. AU - Bobde, J. AU - Bhagat, A. AU - Shaikh, H. AU - Kadam, R. PY - 2018 DA - 2018// TI - Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D JO - J Assoc Physicians India VL - 66 ID - Bhosle2018 ER - TY - JOUR AU - Toth, P. P. AU - Granowitz, C. AU - Hull, M. AU - Liassou, D. AU - Anderson, A. AU - Philip, S. PY - 2018 DA - 2018// TI - High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk JO - J Am Heart Assoc VL - 7 UR - https://doi.org/10.1161/JAHA.118.008740 DO - 10.1161/JAHA.118.008740 ID - Toth2018 ER - TY - JOUR AU - Jain, M. R. AU - Giri, S. R. AU - Bhoi, B. AU - Trivedi, C. AU - Rath, A. AU - Rathod, R. AU - Ranvir, R. AU - Kadam, S. AU - Patel, H. AU - Swain, P. AU - Roy, S. S. PY - 2018 DA - 2018// TI - Dual PPAR α/γ agonist Saroglitazar improves liver histopathology and biochemistry in experimental NASH models JO - Liver Int VL - 38 UR - https://doi.org/10.1111/liv.13634 DO - 10.1111/liv.13634 ID - Jain2018 ER - TY - JOUR AU - Chalasani, N. AU - Younossi, Z. AU - Lavine, J. E. AU - Charlton, M. AU - Cusi, K. AU - Rinella, M. AU - Harrison, S. A. AU - Brunt, E. M. AU - Sanyal, A. J. PY - 2018 DA - 2018// TI - The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases JO - Hepatology VL - 67 UR - https://doi.org/10.1002/hep.29367 DO - 10.1002/hep.29367 ID - Chalasani2018 ER -